Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans
Sangamo Therapeutics Inc. filed for bankruptcy protection in Delaware on Tuesday with offers to sell parts of its genetic therapy development programs to Eli Lilly and Co. and Astellas Pharma Inc....To view the full article, register now.
Already a subscriber? Click here to view full article